The mechanism in more detail
Kisspeptin binds KISS1R on GnRH neurons in the hypothalamus, signalling through the phospholipase C pathway to trigger pulsatile GnRH release. This drives downstream luteinising hormone (LH) and follicle-stimulating hormone (FSH) secretion from the anterior pituitary, and consequently gonadal steroid production, forming the mechanistic basis for its investigational use as an IVF oocyte-maturation trigger in women at high risk of ovarian hyperstimulation syndrome.
In randomised controlled human trials, kisspeptin administration has also been shown to modulate activity in brain regions involved in sexual and attraction processing, including the anterior cingulate cortex, hippocampus, parahippocampus and posterior cingulate, independently of, or alongside, its effects on the hypothalamic-pituitary-gonadal axis. These trials, conducted in men and women with diagnosed hypoactive sexual desire disorder, reported changes in brain activity and, in the male trial, increased penile tumescence in response to sexual visual stimuli, relative to placebo.
Kisspeptin has also been investigated for a possible role in appetite and food intake. A controlled human trial in women with overweight or obesity found no significant effect on hunger, food intake, fullness, or glucose and insulin levels compared with a vehicle control, a genuine null result that should not be read as evidence of a metabolic or weight-management benefit.